Global Scleroderma Therapeutics Databank Market Report

Best Price Guarantee	Length	Publisher	Published Date	SKU
from $2,000	100 Pages	Magna Intelligence	April, 2024	MAIN18750439

Best Price Guarantee
Price	from $2,000
Length	100 Pages
Publisher	Magna Intelligence
Published Date	April, 2024
SKU	MAIN18750439

Global Scleroderma Therapeutics Databank Market Report

The Scleroderma Therapeutics market was valued at $1,728.6 Million in 2022, and is projected to reach $2,688.8 Million by 2031 growing at a CAGR of 5.07% from 2023 to 2031. Immunosuppressors segment is expected to be the highest contributor to this market, with $1,235.9 Million in 2022, and is anticipated to reach $1,832.6 Million by 2031, registering a CAGR of 4.52%. Prostacyclin Analogues segment is anticipated to reach $77.5 Million by 2031 with the highest CAGR of 8.45%. Immunosuppressors and Endothelin Receptor Antagonists segments collectively expected to account for about 84.0% share of the Scleroderma Therapeutics market in 2022, with the former constituting around 71.5% share. Prostacyclin Analogues and Phosphodiesterase 5 Inhibitors - PHA segments are expected to witness significant growth rates at a CAGR of 8.45% and 6.62% respectively, during the forecast period. Presently, share of these two segments is estimated to be around 6.4% in the overall Scleroderma Therapeutics market in 2022, and is anticipated to reach 7.7% by 2031.

1. Global Scleroderma Therapeutics Market, By Drug Class: 1.1. Overview; 1.2. Immunosuppressors; 1.2.1 Immunosuppressors Market, By Region; 1.2.1.1 North America Immunosuppressors Market, By Country; 1.2.1.2 Europe Immunosuppressors Market, By Country; 1.2.1.3 Asia-Pacific Immunosuppressors Market, By Country; 1.2.1.4 Rest of World Immunosuppressors Market, By Country; 1.3. Phosphodiesterase 5 Inhibitors - PHA; 1.3.1 Phosphodiesterase 5 Inhibitors - PHA Market, By Region; 1.3.1.1 North America Phosphodiesterase 5 Inhibitors - PHA Market, By Country; 1.3.1.2 Europe Phosphodiesterase 5 Inhibitors - PHA Market, By Country; 1.3.1.3 Asia-Pacific Phosphodiesterase 5 Inhibitors - PHA Market, By Country; 1.3.1.4 Rest of World Phosphodiesterase 5 Inhibitors - PHA Market, By Country; 1.4. Endothelin Receptor Antagonists; 1.4.1 Endothelin Receptor Antagonists Market, By Region; 1.4.1.1 North America Endothelin Receptor Antagonists Market, By Country; 1.4.1.2 Europe Endothelin Receptor Antagonists Market, By Country; 1.4.1.3 Asia-Pacific Endothelin Receptor Antagonists Market, By Country; 1.4.1.4 Rest of World Endothelin Receptor Antagonists Market, By Country; 1.5. Prostacyclin Analogues; 1.5.1 Prostacyclin Analogues Market, By Region; 1.5.1.1 North America Prostacyclin Analogues Market, By Country; 1.5.1.2 Europe Prostacyclin Analogues Market, By Country; 1.5.1.3 Asia-Pacific Prostacyclin Analogues Market, By Country; 1.5.1.4 Rest of World Prostacyclin Analogues Market, By Country; 1.6. Calcium Channel Blockers; 1.6.1 Calcium Channel Blockers Market, By Region; 1.6.1.1 North America Calcium Channel Blockers Market, By Country; 1.6.1.2 Europe Calcium Channel Blockers Market, By Country; 1.6.1.3 Asia-Pacific Calcium Channel Blockers Market, By Country; 1.6.1.4 Rest of World Calcium Channel Blockers Market, By Country; 1.7. Analgesics; 1.7.1 Analgesics Market, By Region; 1.7.1.1 North America Analgesics Market, By Country; 1.7.1.2 Europe Analgesics Market, By Country; 1.7.1.3 Asia-Pacific Analgesics Market, By Country; 1.7.1.4 Rest of World Analgesics Market, By Country; 1.8. Other Drug Classes; 1.8.1 Other Drug Classes Market, By Region; 1.8.1.1 North America Other Drug Classes Market, By Country; 1.8.1.2 Europe Other Drug Classes Market, By Country; 1.8.1.3 Asia-Pacific Other Drug Classes Market, By Country; 1.8.1.4 Rest of World Other Drug Classes Market, By Country
2. Global Scleroderma Therapeutics Market, By Indication: 2.1. Overview; 2.2. Systemic; 2.2.1 Systemic Market, By Region; 2.2.1.1 North America Systemic Market, By Country; 2.2.1.2 Europe Systemic Market, By Country; 2.2.1.3 Asia-Pacific Systemic Market, By Country; 2.2.1.4 Rest of World Systemic Market, By Country; 2.3. Localized; 2.3.1 Localized Market, By Region; 2.3.1.1 North America Localized Market, By Country; 2.3.1.2 Europe Localized Market, By Country; 2.3.1.3 Asia-Pacific Localized Market, By Country; 2.3.1.4 Rest of World Localized Market, By Country
3. Global Scleroderma Therapeutics Market, By Region: 3.1. Overview; 3.2. North America; 3.2.1 North America Scleroderma Therapeutics Market, By Drug Class; 3.2.2 North America Scleroderma Therapeutics Market, By Indication; 3.2.3 North America Scleroderma Therapeutics Market, By Country; 3.2.3.1 U.S.; 3.2.3.1.1 U.S. Scleroderma Therapeutics Market, By Drug Class; 3.2.3.1.2 U.S. Scleroderma Therapeutics Market, By Indication; 3.2.3.2 Canada; 3.2.3.2.1 Canada Scleroderma Therapeutics Market, By Drug Class; 3.2.3.2.2 Canada Scleroderma Therapeutics Market, By Indication; 3.3. Europe; 3.3.1 Europe Scleroderma Therapeutics Market, By Drug Class; 3.3.2 Europe Scleroderma Therapeutics Market, By Indication; 3.3.3 Europe Scleroderma Therapeutics Market, By Country; 3.3.3.1 Germany; 3.3.3.1.1 Germany Scleroderma Therapeutics Market, By Drug Class; 3.3.3.1.2 Germany Scleroderma Therapeutics Market, By Indication; 3.3.3.2 U.K.; 3.3.3.2.1 U.K. Scleroderma Therapeutics Market, By Drug Class; 3.3.3.2.2 U.K. Scleroderma Therapeutics Market, By Indication; 3.3.3.3 France; 3.3.3.3.1 France Scleroderma Therapeutics Market, By Drug Class; 3.3.3.3.2 France Scleroderma Therapeutics Market, By Indication; 3.3.3.4 Italy; 3.3.3.4.1 Italy Scleroderma Therapeutics Market, By Drug Class; 3.3.3.4.2 Italy Scleroderma Therapeutics Market, By Indication; 3.3.3.5 Spain; 3.3.3.5.1 Spain Scleroderma Therapeutics Market, By Drug Class; 3.3.3.5.2 Spain Scleroderma Therapeutics Market, By Indication; 3.3.3.6 Rest of Europe; 3.3.3.6.1 Rest of Europe Scleroderma Therapeutics Market, By Drug Class; 3.3.3.6.2 Rest of Europe Scleroderma Therapeutics Market, By Indication; 3.4. Asia-Pacific; 3.4.1 Asia-Pacific Scleroderma Therapeutics Market, By Drug Class; 3.4.2 Asia-Pacific Scleroderma Therapeutics Market, By Indication; 3.4.3 Asia-Pacific Scleroderma Therapeutics Market, By Country; 3.4.3.1 China; 3.4.3.1.1 China Scleroderma Therapeutics Market, By Drug Class; 3.4.3.1.2 China Scleroderma Therapeutics Market, By Indication; 3.4.3.2 Japan; 3.4.3.2.1 Japan Scleroderma Therapeutics Market, By Drug Class; 3.4.3.2.2 Japan Scleroderma Therapeutics Market, By Indication; 3.4.3.3 South Korea; 3.4.3.3.1 South Korea Scleroderma Therapeutics Market, By Drug Class; 3.4.3.3.2 South Korea Scleroderma Therapeutics Market, By Indication; 3.4.3.4 India; 3.4.3.4.1 India Scleroderma Therapeutics Market, By Drug Class; 3.4.3.4.2 India Scleroderma Therapeutics Market, By Indication; 3.4.3.5 Singapore; 3.4.3.5.1 Singapore Scleroderma Therapeutics Market, By Drug Class; 3.4.3.5.2 Singapore Scleroderma Therapeutics Market, By Indication; 3.4.3.6 Rest of Asia; 3.4.3.6.1 Rest of Asia Scleroderma Therapeutics Market, By Drug Class; 3.4.3.6.2 Rest of Asia Scleroderma Therapeutics Market, By Indication; 3.5. Rest of World; 3.5.1 Rest of World Scleroderma Therapeutics Market, By Drug Class; 3.5.2 Rest of World Scleroderma Therapeutics Market, By Indication; 3.5.3 Rest of World Scleroderma Therapeutics Market, By Country; 3.5.3.1 Brazil; 3.5.3.1.1 Brazil Scleroderma Therapeutics Market, By Drug Class; 3.5.3.1.2 Brazil Scleroderma Therapeutics Market, By Indication; 3.5.3.2 Mexico; 3.5.3.2.1 Mexico Scleroderma Therapeutics Market, By Drug Class; 3.5.3.2.2 Mexico Scleroderma Therapeutics Market, By Indication; 3.5.3.3 South Africa; 3.5.3.3.1 South Africa Scleroderma Therapeutics Market, By Drug Class; 3.5.3.3.2 South Africa Scleroderma Therapeutics Market, By Indication; 3.5.3.4 Australia; 3.5.3.4.1 Australia Scleroderma Therapeutics Market, By Drug Class; 3.5.3.4.2 Australia Scleroderma Therapeutics Market, By Indication; 3.5.3.5 ROW Countries; 3.5.3.5.1 ROW Countries Scleroderma Therapeutics Market, By Drug Class; 3.5.3.5.2 ROW Countries Scleroderma Therapeutics Market, By Indication; ROW Countries Scleroderma Therapeutics Market Value, By Indication, 2022-2031, Million USD LIST OF TABLES; TABLE 1. Global Scleroderma Therapeutics Market Value, By Drug Class, 2022-2031, Million USD; TABLE 2. Immunosuppressors Market Value, By Region, 2022-2031, Million USD; TABLE 3. North America Immunosuppressors Market Value, By Country, 2022-2031, Million USD; TABLE 4. Europe Immunosuppressors Market Value, By Country, 2022-2031, Million USD; TABLE 5. Asia-Pacific Immunosuppressors Market Value, By Country, 2022-2031, Million USD; TABLE 6. Rest of World Immunosuppressors Market Value, By Country, 2022-2031, Million USD; TABLE 7. Phosphodiesterase 5 Inhibitors - PHA Market Value, By Region, 2022-2031, Million USD; TABLE 8. North America Phosphodiesterase 5 Inhibitors - PHA Market Value, By Country, 2022-2031, Million USD; TABLE 9. Europe Phosphodiesterase 5 Inhibitors - PHA Market Value, By Country, 2022-2031, Million USD; TABLE 10. Asia-Pacific Phosphodiesterase 5 Inhibitors - PHA Market Value, By Country, 2022-2031, Million USD; TABLE 11. Rest of World Phosphodiesterase 5 Inhibitors - PHA Market Value, By Country, 2022-2031, Million USD; TABLE 12. Endothelin Receptor Antagonists Market Value, By Region, 2022-2031, Million USD; TABLE 13. North America Endothelin Receptor Antagonists Market Value, By Country, 2022-2031, Million USD; TABLE 14. Europe Endothelin Receptor Antagonists Market Value, By Country, 2022-2031, Million USD; TABLE 15. Asia-Pacific Endothelin Receptor Antagonists Market Value, By Country, 2022-2031, Million USD; TABLE 16. Rest of World Endothelin Receptor Antagonists Market Value, By Country, 2022-2031, Million USD; TABLE 17. Prostacyclin Analogues Market Value, By Region, 2022-2031, Million USD; TABLE 18. North America Prostacyclin Analogues Market Value, By Country, 2022-2031, Million USD; TABLE 19. Europe Prostacyclin Analogues Market Value, By Country, 2022-2031, Million USD; TABLE 20. Asia-Pacific Prostacyclin Analogues Market Value, By Country, 2022-2031, Million USD; TABLE 21. Rest of World Prostacyclin Analogues Market Value, By Country, 2022-2031, Million USD; TABLE 22. Calcium Channel Blockers Market Value, By Region, 2022-2031, Million USD; TABLE 23. North America Calcium Channel Blockers Market Value, By Country, 2022-2031, Million USD; TABLE 24. Europe Calcium Channel Blockers Market Value, By Country, 2022-2031, Million USD; TABLE 25. Asia-Pacific Calcium Channel Blockers Market Value, By Country, 2022-2031, Million USD; TABLE 26. Rest of World Calcium Channel Blockers Market Value, By Country, 2022-2031, Million USD; TABLE 27. Analgesics Market Value, By Region, 2022-2031, Million USD; TABLE 28. North America Analgesics Market Value, By Country, 2022-2031, Million USD; TABLE 29. Europe Analgesics Market Value, By Country, 2022-2031, Million USD; TABLE 30. Asia-Pacific Analgesics Market Value, By Country, 2022-2031, Million USD; TABLE 31. Rest of World Analgesics Market Value, By Country, 2022-2031, Million USD; TABLE 32. Other Drug Classes Market Value, By Region, 2022-2031, Million USD; TABLE 33. North America Other Drug Classes Market Value, By Country, 2022-2031, Million USD; TABLE 34. Europe Other Drug Classes Market Value, By Country, 2022-2031, Million USD; TABLE 35. Asia-Pacific Other Drug Classes Market Value, By Country, 2022-2031, Million USD; TABLE 36. Rest of World Other Drug Classes Market Value, By Country, 2022-2031, Million USD; TABLE 37. Global Scleroderma Therapeutics Market Value, By Indication, 2022-2031, Million USD; TABLE 38. Systemic Market Value, By Region, 2022-2031, Million USD; TABLE 39. North America Systemic Market Value, By Country, 2022-2031, Million USD; TABLE 40. Europe Systemic Market Value, By Country, 2022-2031, Million USD; TABLE 41. Asia-Pacific Systemic Market Value, By Country, 2022-2031, Million USD; TABLE 42. Rest of World Systemic Market Value, By Country, 2022-2031, Million USD; TABLE 43. Localized Market Value, By Region, 2022-2031, Million USD; TABLE 44. North America Localized Market Value, By Country, 2022-2031, Million USD; TABLE 45. Europe Localized Market Value, By Country, 2022-2031, Million USD; TABLE 46. Asia-Pacific Localized Market Value, By Country, 2022-2031, Million USD; TABLE 47. Rest of World Localized Market Value, By Country, 2022-2031, Million USD; TABLE 48. Global Scleroderma Therapeutics Market Value, By Region, 2022-2031, Million USD; TABLE 49. North America Scleroderma Therapeutics Market Value, By Drug Class, 2022-2031, Million USD; TABLE 50. North America Scleroderma Therapeutics Market Value, By Indication, 2022-2031, Million USD; TABLE 51. North America Scleroderma Therapeutics Market Value, By Country, 2022-2031, Million USD; TABLE 52. U.S. Scleroderma Therapeutics Market Value, By Drug Class, 2022-2031, Million USD; TABLE 53. U.S. Scleroderma Therapeutics Market Value, By Indication, 2022-2031, Million USD; TABLE 54. Canada Scleroderma Therapeutics Market Value, By Drug Class, 2022-2031, Million USD; TABLE 55. Canada Scleroderma Therapeutics Market Value, By Indication, 2022-2031, Million USD; TABLE 56. Europe Scleroderma Therapeutics Market Value, By Drug Class, 2022-2031, Million USD; TABLE 57. Europe Scleroderma Therapeutics Market Value, By Indication, 2022-2031, Million USD; TABLE 58. Europe Scleroderma Therapeutics Market Value, By Country, 2022-2031, Million USD; TABLE 59. Germany Scleroderma Therapeutics Market Value, By Drug Class, 2022-2031, Million USD; TABLE 60. Germany Scleroderma Therapeutics Market Value, By Indication, 2022-2031, Million USD; TABLE 61. U.K. Scleroderma Therapeutics Market Value, By Drug Class, 2022-2031, Million USD; TABLE 62. U.K. Scleroderma Therapeutics Market Value, By Indication, 2022-2031, Million USD; TABLE 63. France Scleroderma Therapeutics Market Value, By Drug Class, 2022-2031, Million USD; TABLE 64. France Scleroderma Therapeutics Market Value, By Indication, 2022-2031, Million USD; TABLE 65. Italy Scleroderma Therapeutics Market Value, By Drug Class, 2022-2031, Million USD; TABLE 66. Italy Scleroderma Therapeutics Market Value, By Indication, 2022-2031, Million USD; TABLE 67. Spain Scleroderma Therapeutics Market Value, By Drug Class, 2022-2031, Million USD; TABLE 68. Spain Scleroderma Therapeutics Market Value, By Indication, 2022-2031, Million USD; TABLE 69. Rest of Europe Scleroderma Therapeutics Market Value, By Drug Class, 2022-2031, Million USD; TABLE 70. Rest of Europe Scleroderma Therapeutics Market Value, By Indication, 2022-2031, Million USD; TABLE 71. Asia-Pacific Scleroderma Therapeutics Market Value, By Drug Class, 2022-2031, Million USD; TABLE 72. Asia-Pacific Scleroderma Therapeutics Market Value, By Indication, 2022-2031, Million USD; TABLE 73. Asia-Pacific Scleroderma Therapeutics Market Value, By Country, 2022-2031, Million USD; TABLE 74. China Scleroderma Therapeutics Market Value, By Drug Class, 2022-2031, Million USD; TABLE 75. China Scleroderma Therapeutics Market Value, By Indication, 2022-2031, Million USD; TABLE 76. Japan Scleroderma Therapeutics Market Value, By Drug Class, 2022-2031, Million USD; TABLE 77. Japan Scleroderma Therapeutics Market Value, By Indication, 2022-2031, Million USD; TABLE 78. South Korea Scleroderma Therapeutics Market Value, By Drug Class, 2022-2031, Million USD; TABLE 79. South Korea Scleroderma Therapeutics Market Value, By Indication, 2022-2031, Million USD; TABLE 80. India Scleroderma Therapeutics Market Value, By Drug Class, 2022-2031, Million USD; TABLE 81. India Scleroderma Therapeutics Market Value, By Indication, 2022-2031, Million USD; TABLE 82. Singapore Scleroderma Therapeutics Market Value, By Drug Class, 2022-2031, Million USD; TABLE 83. Singapore Scleroderma Therapeutics Market Value, By Indication, 2022-2031, Million USD; TABLE 84. Rest of Asia Scleroderma Therapeutics Market Value, By Drug Class, 2022-2031, Million USD; TABLE 85. Rest of Asia Scleroderma Therapeutics Market Value, By Indication, 2022-2031, Million USD; TABLE 86. Rest of World Scleroderma Therapeutics Market Value, By Drug Class, 2022-2031, Million USD; TABLE 87. Rest of World Scleroderma Therapeutics Market Value, By Indication, 2022-2031, Million USD; TABLE 88. Rest of World Scleroderma Therapeutics Market Value, By Country, 2022-2031, Million USD; TABLE 89. Brazil Scleroderma Therapeutics Market Value, By Drug Class, 2022-2031, Million USD; TABLE 90. Brazil Scleroderma Therapeutics Market Value, By Indication, 2022-2031, Million USD; TABLE 91. Mexico Scleroderma Therapeutics Market Value, By Drug Class, 2022-2031, Million USD; TABLE 92. Mexico Scleroderma Therapeutics Market Value, By Indication, 2022-2031, Million USD; TABLE 93. South Africa Scleroderma Therapeutics Market Value, By Drug Class, 2022-2031, Million USD; TABLE 94. South Africa Scleroderma Therapeutics Market Value, By Indication, 2022-2031, Million USD; TABLE 95. Australia Scleroderma Therapeutics Market Value, By Drug Class, 2022-2031, Million USD; TABLE 96. Australia Scleroderma Therapeutics Market Value, By Indication, 2022-2031, Million USD; TABLE 97. ROW Countries Scleroderma Therapeutics Market Value, By Drug Class, 2022-2031, Million USD; TABLE 98. ROW Countries Scleroderma Therapeutics Market Value, By Indication, 2022-2031, Million USD; ROW Countries Scleroderma Therapeutics Market Value, By Indication, 2022-2031, Million USD